CompletedPhase 3NCT01545076
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)
Studying Chronic inflammatory demyelinating polyneuropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- CSL Behring
- Principal Investigator
- Prof. Dr. Ivo N. van SchaikAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Intervention
- IgPro20 (low dose)(biological)
- Enrollment
- 208 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2012 – 2016
Study locations (30)
- Site reference 8400181, Birmingham, Alabama, United States
- Site reference 8400173, Phoenix, Arizona, United States
- Site reference 8400172, Phoenix, Arizona, United States
- Site reference 8400167, Los Angeles, California, United States
- Site reference 8400077, Centennial, Colorado, United States
- Site Reference 8400352, Washington D.C., District of Columbia, United States
- Site reference 8400214, Miami, Florida, United States
- Site reference 8400162, Chicago, Illinois, United States
- Site Reference 8400247, Chicago, Illinois, United States
- Site Reference 8400215, Indianapolis, Indiana, United States
- Site reference 8400166, Kansas City, Kansas, United States
- Site Reference 8400347, New Brunswick, New Jersey, United States
- Site reference 8400169, New York, New York, United States
- Site reference 8400179, New York, New York, United States
- Site reference 8400182, Charlotte, North Carolina, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
ICON Clinical Research
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01545076 on ClinicalTrials.govOther trials for Chronic inflammatory demyelinating polyneuropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07540221A Study to Evaluate the Pharmacokinetics and Safety of XEMBIFY Versus Gamunex-C in Participants With Chronic Inflammatory Demyelinating PolyradiculoneuropathyGrifols Therapeutics LLC
- RECRUITINGPHASE3NCT06752356A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Kedrion S.p.A.
- RECRUITINGNCT07273903Subcutaneous Immunoglobulin Therapy Effectiveness Monitoring in CIDP Patients Using Smart DevicesHeinrich-Heine University, Duesseldorf
- RECRUITINGPHASE3NCT07091630A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDPargenx
- ENROLLING BY INVITATIONPHASE2NCT07188844An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Immunovant Sciences GmbH
- RECRUITINGNCT07154524Immunoadsorption for Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)University of Ulm
- RECRUITINGPHASE3NCT06920004A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDPargenx
- RECRUITINGNCT07264426Real-World Efgartigimod Effectiveness in CIDP: A Prospective Studyargenx
See all trials for Chronic inflammatory demyelinating polyneuropathy →